Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.

Ramírez-Rincón A, Builes-Montaño CE, Hincapié-García JA, Blanco VM, Botero-Arango JF

Frontiers in endocrinology28 Apr 2022Cited by 6 (Europe PMC)

PMID35573995PMCIDPMC9097264DOI10.3389/fendo.2022.828607PepBankPUB-35573995

Summary

BackgroundType 2 diabetes mellitus (T2DM) is a chronic, highly prevalent disease with a significant impact on health. Appropriate treatment requires effective and timely escalation to achieve metabolic control. To evaluate the effectiveness and safety of IDegLira on adults with T2DM previously treated with oral antidiabetics and/or insulin in a real-life setting.MethodsAn observational study in a real-world setting was conducted. Patients were selected from the outpatient clinic of two centers dedicated to specialized diabetes care. Main outcomes were HbA1c, body weight, insulin dose changes, hypoglycemia, and other adverse events.Results67 T2DM patients treated with IDegLira were monitored between 3 and 7 months. At the end of foll ow-up, the median change in HbA1c was -1.05% (CI95% -1.45, -0.65), and a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5). No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline.ConclusionsThis real-life study shows the effectiveness in glycemic control of IDegLira use in T2DM patients who do not achieve goals with other therapies, with an adequate safety profile. The findings need to be confirmed with evaluation of therapeutic results in larger cohorts.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, the fixed-dose combination IDegLira (insulin degludec/liraglutide) was followed by a median HbA1c change of -1.05% after 3 to 7 months.
In plain wordsIn adults with type 2 diabetes, HbA1c fell after treatment with the combination product IDegLira in routine care.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change at end of follow-up
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Measurements
Median HbA1c change
−1.05%
end of follow-up
Source sentences
Summary
the median change in HbA1c was -1.05% (CI95% -1.45, -0.65)
1 context sentence(design, population, supporting numbers)
Summary · context
67 T2DM patients treated with IDegLira were monitored between 3 and 7 months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3557399501
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with type 2 diabetes in routine care, insulin requirement fell (mean difference -10 total daily dose units) after treatment with the fixed-dose combination IDegLira.
In plain wordsIn adults with type 2 diabetes, the insulin dose needed fell after treatment with the combination product IDegLira.
Peptide
Liraglutide
Outcome
DecreaseInsulin requirement change
Study
n = 67
Outcome group
Glycemic control · Metabolic and weight
Measurements
Mean difference in total daily dose
−10 units
end of follow-up
Source sentences
Summary
a decrease in insulin requirement was also observed (mean difference -10 TDD units (CI95% - 17 to -2.5).
1 context sentence(design, population, supporting numbers)
Summary · context
67 T2DM patients treated with IDegLira were monitored between 3 and 7 months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3557399502
03HumanNot a test of Liraglutide aloneObservational studySafety outcome
In adults with type 2 diabetes in routine care, no treatment discontinuation was reported with the fixed-dose combination IDegLira.
In plain wordsIn adults with type 2 diabetes, nobody stopped the combination product IDegLira during follow-up.
Peptide
Liraglutide
Outcome
No significant changeTreatment discontinuation
Study
n = 67
Outcome group
Adverse events · Whole body
Source sentences
Summary
No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
67 T2DM patients treated with IDegLira were monitored between 3 and 7 months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3557399503
04HumanNot a test of Liraglutide aloneObservational studySafety outcome
In adults with type 2 diabetes in routine care, hypoglycemia events occurred in 3 patients at the end of follow-up versus 8 patients at baseline with IDegLira treatment.
In plain wordsIn adults with type 2 diabetes, fewer people had low blood sugar events after treatment with the combination product IDegLira than at baseline.
Peptide
Liraglutide
Outcome
DecreaseHypoglycemia events
Study
n = 67
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
No treatment discontinuation was reported, hypoglycemia events were reported in 3 patients at the end of follow-up versus 8 patients at baseline.
1 context sentence(design, population, supporting numbers)
Summary · context
67 T2DM patients treated with IDegLira were monitored between 3 and 7 months.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Show in the study text Report a problemFND-3557399504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.